Semaphorin 3E Suppresses Tumor Cell Death Triggered by the Plexin D1 Dependence Receptor in Metastatic Breast Cancers

Cancer Cell

Volumn 24, Issue 5, 2013, Pages 673-685

  Luchino, Jonathan ^a   Hocine, Mélanie ^a   Amoureux, Marie Claude ^a   Gibert, Benjamin ^b   Bernet, Agnès ^b,c   Royet, Amélie ^b,c   Treilleux, Isabelle ^c   Lécine, Patrick ^d,e   Borg, Jean Paul ^d   Mehlen, Patrick ^b   Chauvet, Sophie ^a   Mann, Fanny ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE LÉON BÉRARD   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR RECEPTOR NUR77; PLEXIN; PLEXIN D1 PROTEIN; SEMAPHORIN; SEMAPHORIN 3E; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST METASTASIS; CANCER GROWTH; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

EID: 84887559933     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.09.010     Document Type: Article

References (42)

1. Alexopoulou A.N., Leao M., Caballero O.L., Da Silva L., Reid L., Lakhani S.R., Simpson A.J., Marshall J.F., Neville A.M., Jat P.S. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res. 2010, 12:R51.
2. Aslakson C.J., Miller F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52:1399-1405.
3. Ballard M.S., Hinck L. A roundabout way to cancer. Adv. Cancer Res. 2012, 114:187-235.
4. Bernet A., Mazelin L., Coissieux M.M., Gadot N., Ackerman S.L., Scoazec J.Y., Mehlen P. Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology 2007, 133:1840-1848.
5. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.M., Wu J., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405. Australian Pancreatic Cancer Genome Initiative.
6. Bouzas-Rodriguez J., Cabrera J.R., Delloye-Bourgeois C., Ichim G., Delcros J.G., Raquin M.A., Rousseau R., Combaret V., Bénard J., Tauszig-Delamasure S., Mehlen P. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J.Clin. Invest. 2010, 120:850-858.
7. Casazza A., Finisguerra V., Capparuccia L., Camperi A., Swiercz J.M., Rizzolio S., Rolny C., Christensen C., Bertotti A., Sarotto I., et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J.Clin. Invest. 2010, 120:2684-2698.
8. Casazza A., Kigel B., Maione F., Capparuccia L., Kessler O., Giraudo E., Mazzone M., Neufeld G., Tamagnone L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med. 2012, 4:234-250.
9. Castets M., Broutier L., Molin Y., Brevet M., Chazot G., Gadot N., Paquet A., Mazelin L., Jarrosson-Wuilleme L., Scoazec J.Y., et al. DCC constrains tumour progression via its dependence receptor activity. Nature 2012, 482:534-537.
10. Chen J. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv. Cancer Res. 2012, 114:1-20.
11. Christensen C.R., Klingelhöfer J., Tarabykina S., Hulgaard E.F., Kramerov D., Lukanidin E. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res. 1998, 58:1238-1244.
12. Christensen C., Ambartsumian N., Gilestro G., Thomsen B., Comoglio P., Tamagnone L., Guldberg P., Lukanidin E. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res. 2005, 65:6167-6177.
13. Coissieux M.M., Tomsic J., Castets M., Hampel H., Tuupanen S., Andrieu N., Comeras I., Drouet Y., Lasset C., Liyanarachchi S., et al. Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. Gastroenterology 2011, 141:2039-2046.
14. Fitamant J., Guenebeaud C., Coissieux M.M., Guix C., Treilleux I., Scoazec J.Y., Bachelot T., Bernet A., Mehlen P. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc. Natl. Acad. Sci. USA 2008, 105:4850-4855.
15. Fombonne J., Bissey P.A., Guix C., Sadoul R., Thibert C., Mehlen P. Patched dependence receptor triggers apoptosis through ubiquitination of caspase-9. Proc. Natl. Acad. Sci. USA 2012, 109:10510-10515.
16. Gaya A., Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat. Rev. 2012, 38:484-493.
17. Genevois A.L., Ichim G., Coissieux M.M., Lambert M.P., Lavial F., Goldschneider D., Jarrosson-Wuilleme L., Lepinasse F., Gouysse G., Herceg Z., et al. Dependence receptor TrkC is a putative colon cancer tumor suppressor. Proc. Natl. Acad. Sci. USA 2013, 110:3017-3022.
18. Goldschneider D., Mehlen P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010, 29:1865-1882.
19. Gu C., Yoshida Y., Livet J., Reimert D.V., Mann F., Merte J., Henderson C.E., Jessell T.M., Kolodkin A.L., Ginty D.D. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307:265-268.
20. Janssen B.J., Robinson R.A., Pérez-Brangulí F., Bell C.H., Mitchell K.J., Siebold C., Jones E.Y. Structural basis of semaphorin-plexin signalling. Nature 2010, 467:1118-1122.
21. Kaur P., Nagaraja G.M., Zheng H., Gizachew D., Galukande M., Krishnan S., Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer 2012, 12:120.
22. Kigel B., Varshavsky A., Kessler O., Neufeld G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS ONE 2008, 3:e3287.
23. Lee S.O., Li X., Khan S., Safe S. Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opin. Ther. Targets 2011, 15:195-206.
24. Li H., Kolluri S.K., Gu J., Dawson M.I., Cao X., Hobbs P.D., Lin B., Chen G., Lu J., Lin F., et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000, 289:1159-1164.
25. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., Dawson M.I., Reed J.C., Zhang X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116:527-540.
26. Mille F., Thibert C., Fombonne J., Rama N., Guix C., Hayashi H., Corset V., Reed J.C., Mehlen P. The Patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat. Cell Biol. 2009, 11:739-746.
27. Mohan H.M., Aherne C.M., Rogers A.C., Baird A.W., Winter D.C., Murphy E.P. Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. Clin. Cancer Res. 2012, 18:3223-3228.
28. Moll U.M., Marchenko N., Zhang X.K. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 2006, 25:4725-4743.
29. Muscat G.E., Eriksson N.A., Byth K., Loi S., Graham D., Jindal S., Davis M.J., Clyne C., Funder J.W., Simpson E.R., et al. Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol. Endocrinol. 2013, 27:350-365.
30. Rehman M., Tamagnone L. Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin. Cell Dev. Biol. 2013, 24:179-189.
31. Roodink I., Raats J., van der Zwaag B., Verrijp K., Kusters B., van Bokhoven H., Linkels M., de Waal R.M., Leenders W.P. Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy?. Cancer Res. 2005, 65:8317-8323.
32. Roodink I., Verrijp K., Raats J., Leenders W.P. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer 2009, 9:297.
33. Rose D.P., Connolly J.M., Liu X.H. Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines invitro. Cancer Res. 1994, 54:6557-6562.
34. Sabag A.D., Bode J., Fink D., Kigel B., Kugler W., Neufeld G. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain. PLoS ONE 2012, 7:e42912.
35. Shalaby M.A., Hampson L., Oliver A., Hampson I. Plexin D1: new potential biomarker for cervical cancer. J.Immunoassay Immunochem. 2012, 33:223-233.
36. Siebold C., Jones E.Y. Structural insights into semaphorins and their receptors. Semin. Cell Dev. Biol. 2013, 24:139-145.
37. Tamagnone L., Artigiani S., Chen H., He Z., Ming G.I., Song H., Chedotal A., Winberg M.L., Goodman C.S., Poo M., et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999, 99:71-80.
38. To S.K., Zeng J.Z., Wong A.S. Nur77: a potential therapeutic target in cancer. Expert Opin. Ther. Targets 2012, 16:573-585.
39. Toyofuku T., Yabuki M., Kamei J., Kamei M., Makino N., Kumanogoh A., Hori M. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J. 2007, 26:1373-1384.
40. Tseng C.H., Murray K.D., Jou M.F., Hsu S.M., Cheng H.J., Huang P.H. Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS ONE 2011, 6:e19396.
41. Uesugi K., Oinuma I., Katoh H., Negishi M. Different requirement for Rnd GTPases of R-Ras GAP activity of Plexin-C1 and Plexin-D1. J.Biol. Chem. 2009, 284:6743-6751.
42. Wilson A.J., Arango D., Mariadason J.M., Heerdt B.G., Augenlicht L.H. TR3/Nur77 in colon cancer cell apoptosis. Cancer Res. 2003, 63:5401-5407.